Advertisements


Why Celldex Therapeutics Is Getting Crushed

Celldex Therapeutics shares were absolutely crushed on Monday morning after the firm announced results to its midstage breast cancer study......»»

Category: blogSource: 247wallstApr 16th, 2018

Better Buy: Ziopharm Oncology, Inc. vs. Celldex Therapeutics

Which beaten-down biotech stock wins in a head-to-head match-up?.....»»

Category: topSource: foxnewsJun 29th, 2018

Why Summit Therapeutics Was Crushed

Summit Therapeutics is another biopharma company that is paying the price on Wednesday......»»

Category: blogSource: 247wallstJun 27th, 2018

Celldex Therapeutics Salvage Value

Celldex Therapeutics Salvage Value.....»»

Category: topSource: seekingalphaJun 15th, 2018

Celldex Therapeutics (CLDX) Down 9.2% Since Earnings Report: Can It Rebound?

Zacks.....»»

Category: topSource: redinewsJun 11th, 2018

Why Melinta Therapeutics Shares Are Getting Crushed

Melinta Therapeutics saw its shares plunge on Thursday after the firm announced that it had priced a secondary offering......»»

Category: blogSource: 247wallstMay 24th, 2018

What"s in Store for Celldex (CLDX) This Earnings Season?

With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus is on i.....»»

Category: personnelSource: nytMay 3rd, 2018

MGIC, Juniper Networks Slide into Wednesday’s 52-Week Low Club

MGIC Investment Group, Celldex Therapeutics, Juniper Networks, and Healthcare Services Group all posted new 52-week lows on Wednesday......»»

Category: blogSource: 247wallstApr 18th, 2018

Celldex"s Phase II Breast Cancer Study Fails, Shares Plunge

Celldex Therapeutics' (CLDX) glembatumumab vedotin fails to meet primary endpoint in phase IIb METRIC study in metastat.....»»

Category: smallbizSource: nytApr 17th, 2018

Celldex, Acacia Plummet into Monday’s 52-Week Low Club

Celldex Therapeutics, Acacia Communications, Apricus Biosciences, and Ctrp.com all posted new 52-week lows Monday......»»

Category: blogSource: 247wallstApr 16th, 2018

Celldex"s stock plummets toward record low after failed drug study

Shares of Celldex Therapeutics Inc. plummeted 40% in premarket trade Monday toward a record low, after the drug.....»»

Category: topSource: marketwatchApr 16th, 2018

Why Skechers Is Getting Crushed

Sketchers released mixed second-quarter financial results after the markets closed on Thursday. It didn’t help the company that analysts piled on, sending shares down even further......»»

Category: blogSource: 247wallst11 hr. 23 min. ago

PTC Therapeutics (PTCT) To Acquire Agilis Biotherapeutics for $200M upfront - Slideshow

PTC Therapeutics (PTCT) To Acquire Agilis Biotherapeutics for $200M upfront - Slideshow.....»»

Category: topSource: seekingalpha13 hr. 23 min. ago

PTC Therapeutics Wins Big With Agilis Biotherapeutics Acquisition

PTC Therapeutics shares made a handy gain on Friday after the firm announced that it would be acquiring Agilis Biotherapeutics......»»

Category: blogSource: 247wallst13 hr. 53 min. ago

Viking Therapeutics call volume above normal and directionally bullish

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewall14 hr. 53 min. ago

Osiris Therapeutics: Actions Speak Louder Than Words

Osiris Therapeutics: Actions Speak Louder Than Words.....»»

Category: topSource: seekingalpha15 hr. 9 min. ago

Why Sketchers Is Getting Crushed

Sketchers released mixed second-quarter financial results after the markets closed on Thursday. It didn’t help the company that analysts piled on, sending shares down even further......»»

Category: blogSource: 247wallst15 hr. 53 min. ago

Stocks aren"t ignoring Trump"s Fed, EU, and China comments. Wall Street"s just watching the dollar get crushed

U.S. stocks were edging higher early Friday, seemingly i.....»»

Category: topSource: marketwatch16 hr. 39 min. ago

Akcea Therapeutics: What The EU Tegsedi Approval Foretells

Akcea Therapeutics: What The EU Tegsedi Approval Foretells.....»»

Category: topSource: seekingalpha19 hr. 39 min. ago

Mersana Therapeutics price target lowered to $16 from $33 at H.C. Wainwright

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewall19 hr. 53 min. ago

Mirati Therapeutics price target raised to $63 from $42 at H.C. Wainwright

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewall19 hr. 53 min. ago